Patents by Inventor Simone Thomas

Simone Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPCIDIN ANALOGUES AND USES THEREOF
    Publication number: 20240174726
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: September 28, 2023
    Publication date: May 30, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie SMYTHE, Gregory Thomas BOURNE, Simone VINK, Brian Troy FREDERICK, Praveen MADALA, Anne Pernille TOFTENG SHELTON, Jacob Ulrik FOG
  • Method for Improving the Specific Effector Functions of Single-Chain-Antigen-Recognizing Genetic Constructs (scARC) Through Murinization Thereof
    Publication number: 20160264642
    Abstract: The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scARC), comprising a genetic construct of the human scARC to be expressed, comprising the domains huV1/2-Li-huV2/1-C4/3 and a genetic construct comprising the corresponding hetero-/(homo-)dimeric domain C3/4, containing xenogenic, in its special case murine amino acid exchanges in the domains C4/3 and C3/4, wherein co-expression of the genetic constructs of the scARC-fragments occurs through the cell. Preferably, the scARCs are single chain-TCRs (scTCRs) or antibody-scFv-fragments, which further preferably recognize tumor associated peptide antigens (TAA). The present invention further relates to a gp100-protein-specific T-cell response mediated ?/? T-cell receptor rationally mutated by means of the method of the present invention and its uses.
    Type: Application
    Filed: May 30, 2016
    Publication date: September 15, 2016
    Inventors: Ralf-Holger VOSS, Matthias THEOBALD, Ratna Sari Intan PÖNDL, Renate ENGEL, Simone THOMAS
  • Method for improving the specific effector function of single-chain antigen-recognizing genetic constructs (scARC) through murinization thereof
    Patent number: 9376482
    Abstract: The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scARC), comprising a genetic construct of the human scARC to be expressed, comprising the domains huV1/2—Li-huV2/1—C4/3 and a genetic construct comprising the corresponding hetero-/(homo-)dimeric domain C3/4, containing xenogenic, in its special case murine amino acid exchanges in the domains C4/3 and C3/4, wherein co-expression of the genetic constructs of the scARC-fragments occurs through the cell. Preferably, the scARCs are single chain-TCRs (scTCRs) or antibody-scFv-fragments, which further preferably recognize tumor associated peptide antigens (TAA). The present invention further relates to a gp100-protein-specific T-cell response mediated ?/? T-cell receptor rationally mutated by means of the method of the present invention and its uses.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: June 28, 2016
    Assignee: Johannes Gutenberg-Universität Mainz
    Inventors: Ralf-Holger Voss, Matthias Theobald, Ratna Sari Intan Pöndl, Renate Engel, Simone Thomas
  • Method for Improving the Specific Effector Function of Single-Chain Antigen-Recognizing Genetic Constructs (SCARC) Through Murinization Thereof
    Publication number: 20100143315
    Abstract: The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scARC), comprising a genetic construct of the human scARC to be expressed, comprising the domains huV1/2—Li-huV2/1—C4/3 and a genetic construct comprising the corresponding hetero-/(homo-)dimeric domain C3/4, containing xenogenic, in its special case murine amino acid exchanges in the domains C4/3 and C3/4, wherein co-expression of the genetic constructs of the scARC-fragments occurs through the cell. Preferably, the scARCs are single chain-TCRs (scTCRs) or antibody-scFv-fragments, which further preferably recognize tumor associated peptide antigens (TAA). The present invention further relates to a gp100-protein-specific T-cell response mediated ?/? T-cell receptor rationally mutated by means of the method of the present invention and its uses.
    Type: Application
    Filed: August 31, 2007
    Publication date: June 10, 2010
    Inventors: Ralf-Holger Voss, Matthias Theobald, Ratna Sari Intan Pöndl, Renate Engel, Simone Thomas
  • Ram head hitch accessory
    Patent number: D865578
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: November 5, 2019
    Inventors: Curtis Thomas, Simone Thomas